| Market Capitalization (Millions $) |
167 |
| Shares
Outstanding (Millions) |
49 |
| Employees |
102 |
| Revenues (TTM) (Millions $) |
230 |
| Net Income (TTM) (Millions $) |
30 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
0 |
Puma Biotechnology Inc
Puma Biotechnology Inc. is an American biopharmaceutical company founded in 2010 and headquartered in Los Angeles, California. The company specializes in the development of innovative drugs for the treatment of cancer, with a particular focus on breast cancer, the second most common cancer in women worldwide.
Puma Biotechnology's main product candidate is Neratinib, a small molecule tyrosine kinase inhibitor (TKI) that targets HER2 (human epidermal growth factor receptor 2), a receptor that is overexpressed in approximately 20% of breast cancer patients. HER2 overexpression is associated with more aggressive tumors, higher rates of recurrence, and poorer prognosis.
Neratinib is being developed as an extended adjuvant therapy for patients with HER2-positive early stage breast cancer who have completed standard of care treatment with trastuzumab, another HER2-targeted therapy, and chemotherapy. The extended adjuvant therapy with neratinib is intended to reduce the risk of disease recurrence and improve overall survival.
Puma Biotechnology completed several pivotal clinical trials of neratinib, including the Phase III ExteNET trial, which enrolled over 2,800 patients and demonstrated a statistically significant improvement in disease-free survival compared to placebo. The company has also conducted clinical trials of neratinib in other HER2-positive cancers, including metastatic breast cancer, HER2-mutant solid tumors, and glioblastoma.
In addition to neratinib, Puma Biotechnology has a pipeline of other drug candidates in preclinical and clinical development, including PB272 (neratinib in combination with another TKI), PB357 (a novel kinase inhibitor), and PB891 (an antibody-drug conjugate).
Puma Biotechnology has a global commercialization agreement with Pierre Fabre, a French pharmaceutical company, for the commercialization of neratinib in Europe, Latin America, Africa, and select other countries. The company also has licensing agreements with various academic institutions and biotech companies for the development of its drug candidates.
The company has a market capitalization of approximately $6 billion as of August 2021 and employs approximately 200 people. Puma Biotechnology is publicly traded on the NASDAQ stock exchange under the ticker symbol PBYI.
Company Address: 10880 Wilshire Boulevard, Suite 2150 Los Angeles 90024 CA
Company Phone Number: 248-6500 Stock Exchange / Ticker: NASDAQ PBYI
|
0.09%